TY  - JOUR
T1  - DUal-binding antibody
AU  - Kuehn BM
Y1  - 2009/05/06
N1  - 10.1001/jama.2009.568
JO  - JAMA
SP  - 1758
EP  - 1758
VL  - 301
IS  - 17
N2  - 
The researchers isolated a variant of the monoclonal antibody biologic trastuzumab, which binds to the human epidermal growth factor receptor 2 (HER2); this variant also can bind vascular endothelial growth factor (VEGF) (Bostrum J et al. Science. 2009;323[5921]:1610-1614). The scientists visualized the structure of this 2-protein–binding variant using x-ray crystallography. Additionally, they found that a trastuzumab variant with high affinity for both HER2 and VEGF can inhibit cell proliferation mediated by these 2 proteins in a human cell line and inhibit tumor progression mediated by these proteins in a mouse model.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2009.568
UR  - http://dx.doi.org/10.1001/jama.2009.568
ER  -